ALK inhibitors in non-small cell lung cancer: The latest evidence and developments

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 1, 2016, Pages 32-47

  Sullivan, Ivana ^a   Planchard, David ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Alectinib; ALK rearrangement; Ceritinib; Crizotinib; NSCLC; Resistance

Indexed keywords

2 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 4 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO] 1,3,5 TRIAZINE; 6 AMINO 5 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] N [4 (4 METHYL 1 PIPERAZINYLCARBONYL)PHENYL] 3 PYRIDAZINECARBOXAMIDE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BRIGATINIB; CEP 28122; CEP 37440; CERITINIB; CRIZOTINIB; ENTRECTINIB; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; LORLATINIB; LUMINESPIB; ONALESPIB; TSR 011; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84951790397     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015617355     Document Type: Review

References (86)

1. Ardini E. Menichincheri M. Banfi P. Saccardo M. Rusconi L. Avanzi N. et al. (2011) In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. Mol Cancer Ther 10: A232.
2. Ardini E. Menichincheri M. de Ponti C. Amboldi N. Saccardo M. Teixido G. et al. (2009) Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Ther 8: A243.
3. Arkenau H. Sachdev J. Mita M. Dziadziuszko R. Lin C. Yang J. et al. (2015) Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. J Clin Oncol 33: 8063.
4. Arnedos M. Vielh P. Soria J. Andre F. (2014) The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 232: 274–282.
5. Bergethon K. Shaw A. Ignatius Ou S. Katayama R. Lovly C. McDonald N. et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863–870.
6. Brahmer J. Pardoll D. (2013) Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 1: 85–91.
7. Camidge D. Bang Y. Kwak E. Iafrate A. Varella-Garcia M. Fox S. et al. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13: 1011–1019.
8. Camidge D. Bazhenova L. Salgia R. Langer C. Gold K. Rosell R. et al. (2015) Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 33: 8062.
9. Camidge D. Kono S. Flacco A. Tan A. Doebele R. Zhou Q. et al. (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16: 5581–5590.
10. Cardarella S. Johnson B. (2013) The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 188: 770–775.
11. Cheng M. Quail M. Gingrich D. Ott G. Lu L. Wan W. et al. (2012) CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 11: 670–679.
12. Choi Y. Soda M. Yamashita Y. Ueno T. Takashima J. Nakajima T. et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734–1739.
13. Clarke J. Pao W. Wu N. Miller V. Lassman A. (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99: 283–286.
14. Costa D. Kobayashi S. Pandya S. Yeo W. Shen Z. Tan W. et al. (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29: e443–e445.
15. Costa D. Shaw A. Ignatius Ou S. Solomon B. Riely G. Ahn M. et al. (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33: 1881–1888.
16. Crinò L. Kim D. Riely G. Janne P. Blackhall F. Camidge D. et al. (2011) Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 29: 7514.
17. de Braud F. Niger M. Damian S. Bardazza B. Martinetti A. Pelossi G. et al. (2015) Alka-372–001: first-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 33: 2517.
18. de Braud F. Pilla L. Niger M. Damian S. Bardazza B. Martinetti A. et al. (2014) Phase 1 open label, dose escalation study of RXDX101, an oral Pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 32: 2502.
19. Doebele R. Pilling A. Aisner D. Kutateladze T. Le A. Weickhardt A. et al. (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18: 1472–1482.
20. Ettinger D. Akerley W. Bepler G. Blum M. Chang A. Cheney R. et al. (2010) Non-small cell lung cancer. J Natl Compr Cancer Netw 8: 740–801.
21. Felip E. Carcereny E. Barlesi F. Gandhi L. Sequist L. Kim S. et al. (2012) Phase II activity of the HSP 90 inhibitor AUY 922 in patients with ALK-rearranged (ALK+) or AGFR-mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol 23: ix152–ix174.
22. Felip E. Kim D. Mehra R. Tan D. Chow L. Camidge D. et al. (2014) Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Ann Oncol 25: iv426–iv470.
23. Felip E. Orlov S. Park K. Yu C. Tsai C. Nishio M. et al. (2015) ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol 33: 8060.
24. Ferlay J. Soerjomataram I. Dikshit R. Eser S. Mathers C. Rebelo M. et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359–E386.
25. Friboulet L. Li N. Katayama R. Lee C. Gainor J. Crystal A. et al. (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4: 662–673.
26. Gadgeel S. Gandhi L. Riely G. Chiappori A. West H. Azada M. et al. (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1 / 2 study. Lancet Oncol 15: 1119–1128.
27. Gainor J. Ignatius Ou S. Logan J. Borges L. Shaw A. (2013) The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 8: 1570–1573.
28. Gandhi L. Drappatz J. Ramaiya N. Otterson G. (2013) High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 8: e3–e5.
29. Gandhi L. Shaw A. Gadgeel S. Riely G. Cetnar J. West H. et al. (2015) A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) US / Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol 33: 8019.
30. Gerber D. Minna J. (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18: 548–551.
31. Heuckmann J. Balke-Want H. Malchers F. Peifer M. Sos M. Koker M. et al. (2012) Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 18: 4682–4690.
32. Horn L. Infante J. Blumenschein G. Wakelee H. Arkenau H. Dukart G. et al. (2014) A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol 32: 8030.
33. Ignatius Ou S. Ahn J. de Petris L. Govindan R. Yang J. Hughes B. et al. (2015) Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol 33: 8008.
34. Ignatius Ou S. Azada M. Hsiang D. Herman J. Kain T. Siwak-Tapp C. et al. (2014) Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 9: 549–553.
35. Jackman D. Holmes A. Lindeman N. Wen P. Kesari S. Borras A. et al. (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24: 4517–4520.
36. Johnson T. Richardson P. Bailey S. Brooun A. Burke B. Collins M. et al. (2014) Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.J Med Chem 57: 4720–4744.
37. Katayama R. Khan T. Benes C. Lifshits E. Ebi H. Rivera V. et al. (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U.S. A. 108: 7535–7540.
38. Katayama R. Shaw A. Khan T. Mino-Kenudson M. Solomon B. Halmos B. et al. (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 4: 120ra17.
39. Kim Y. Ozasa H. Nagai H. Sakamori Y. Yoshida H. Yagi Y. et al. (2013) High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 8: e85–e86.
40. Kinoshita K. Asoh K. Furuichi N. Ito T. Kawada H. Hara S. et al. (2012) Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 20: 1271–1280.
41. Koivunen J. Mermel C. Zejnullahu K. Murphy C. Lifshits E. Holmes A. et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275–4283.
42. Kwak E. Bang Y. Camidge D. Shaw A. Solomon B. Maki R. et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693–1703.
43. Larsen J. Cascone T. Gerber D. Heymach J. Minna J. (2011) Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 17: 512–527.
44. Li T. Kung H. Mack P. Gandara D. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31: 1039–1049.
45. Lovly C. Heuckmann J. de Stanchina E. Chen H. Thomas R. Liang C. et al. (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71: 4920–4931.
46. Maitland M. Ignatius Ou S. Tolcher A. LoRusso P. Bahceci E. Ball H. et al. (2014) Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. J Clin Oncol 32: 2624.
47. Marsilje T. Pei W. Chen B. Lu W. Uno T. Jin Y. et al. (2013) Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 56: 5675–5690.
48. Meric-Bernstam F. Farhangfar C. Mendelsohn J. Mills G. (2013) Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 31: 1849–1857.
49. Metro G. Lunardi G. Floridi P. Pascali J. Marcomigni L. Chiari R. et al. (2015) CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol 10: e26–e27.
50. Mok T. Spigel D. Felip E. de Marinis F. Ahn M. Groen H. et al. (2015) ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol 33: 8059.
51. Moreira A. Thornton R. (2012) Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer 13: 334–339.
52. Morris S. Kirstein M. Valentine M. Dittmer K. Shapiro D. Saltman D. et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281–1284.
53. Motl S. Zhuang Y. Waters C. Stewart C. (2006) Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 45: 871–903.
54. Normant E. Paez G. West K. Lim A. Slocum K. Tunkey C. et al. (2011) The Hsp 90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30: 2581–2586.
55. Orscheschek K. Merz H. Hell J. Binder T. Bartels H. Feller A. (1995) Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis? Lancet 345: 87–90.
56. Ou S. (2012) Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Rev Anticancer Ther 12: 151–162.
57. Ou S. Kwak E. Siwak-Tapp C. Dy J. Bergethon K. Clark J. et al. (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6: 942–946.
58. Patel M. Bauer T. Liu S. Drilon A. Wheler J. Shaw A. et al. (2015) STARTRK-1: phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 33: 2596.
59. Patnaik A. LoRusso P. Ball H. Bahceci E. Yuen G. Papadopoulos K. et al. (2013) Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial. J Clin Oncol 31: 2602.
60. Paz-Ares L. Horn L. Borghaei H. Spigel D. Steins M. Ready N. et al. (2015) Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 33: LBA109.
61. Rivera V. Wang F. Anjum R. Zhang S. Squillace R. Keats J. et al. (2012) AP 26113 is a dual ALK / EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Res 72: 1794.
62. Sakamoto H. Tsukaguchi T. Hiroshima S. Kodama T. Kobayashi T. Fukami T. et al. (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19: 679–690.
63. Sasaki T. Koivunen J. Ogino A. Yanagita M. Nikiforow S. Zheng W. et al. (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71: 6051–6060.
64. Sasaki T. Rodig S. Chirieac L. Jänne P. (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46: 1773–1780.
65. Sequist L. Gettinger S. Senzer N. Martins R. Jänne P. Lilenbaum R. et al. (2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28: 4953–4960.
66. Seto T. Kiura K. Nishio M. Nakagawa K. Maemondo M. Inoue A. et al. (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol 14: 590–598.
67. Shaw A. Bauer T. Felip E. Besse B. James L. Clancy J. et al. (2015) Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol 33: 8018.
68. Shaw A. Kim D. Mehra R. Tan D. Felip E. Chow L. et al. (2014 a) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370: 1189–1197.
69. Shaw A. Kim D. Nakagawa K. Seto T. Crinó L. Ahn M. et al. (2013 a) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385–2394.
70. Shaw A. Mehra R. Kim D. Felip E. Chow L. Camidge R. et al. (2013 b) Clinical activity of the ALK inhibitor LDK 378 in advanced, ALK-positive NSCLC. J Clin Oncol 31: 8010.
71. Shaw A. Mehra R. Tan D. Felip E. Chow L. Camidge D. et al. (2014 b) Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND-1 trial. Neuro Oncol 16: v39.
72. Shaw A. Yeap B. Mino-Kenudson M. Digumarthy S. Costa D. Heist R. et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247–4253.
73. Socinski M. Goldman J. El-Hariry I. Koczywas M. Vukovic V. Horn L. et al. (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19: 3068–3077.
74. Soda M. Choi Y. Enomoto M. Takada S. Yamashita Y. Ishikawa S. et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.
75. Solomon B. Mok T. Kim D. Wu Y. Nakagawa K. Mekhail T. et al. (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167–2177.
76. Squillace R. Anjum R. Miller D. Vodala S. Moran L. Wang F. et al. (2013) AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS 1 fusions. Cancer Res 73: 5655.
77. Taipale M. Jarosz D. Lindquist S. (2010) HSP 90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515–528.
78. Takahashi T. Sonobe M. Kobayashi M. Yoshizawa A. Menju T. Nakayama E. et al. (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17: 889–897.
79. Takeda M. Okamoto I. Nakagawa K. (2013) Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8: 654–657.
80. Tamura T. Seto T. Nakagawa K. Maemondo M. Inoue A. Hida T. et al. (2014) Updated data of a phase 1 / 2 study (AF-001JP) of alectinib, a CNS-penetrant, highly selective ALK inhibitor in ALK-rearranged advanced NSCLC. Radiat Oncol 90: S6. DOI: 10.1016/j.ijrobp.2014.08.031.
81. Ullrich A. Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203–212.
82. Vaishnavi A. Capelletti M. Le A. Kako S. Butaney M. Ercan D. et al. (2013) Oncogenic and drug-sensitive NTRK 1 rearrangements in lung cancer. Nat Med 19: 1469–1472.
83. Weiss G. Sachdev J. Infante J. Mita M. Wilcoxen K. Kansra V. et al. (2013) TSR-011, a potent ALK inhibitor with clinical activity in phase I / IIa development. J Thorac Oncol 8: S618.
84. Whitesell L. Lindquist S. (2005) HSP 90 and the chaperoning of cancer. Nat Rev Cancer 5: 761–772.
85. Wong D. Leung E. So K. Tam I. Sihoe A. Cheng L. et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723–1733.
86. Zhang S. Wang F. Keats J. Ning Y. Wardwell S. Moran L. et al. (2010) AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066. Cancer Res 70: LB-298.